Alliance Presents Results from Phase III ATOMIC Trial Combining Atezolizumab with Chemotherapy for Patients with Stage III dMMR Colon Cancer at ASCO 2025

June 1, 2025

The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch re

• Read more

Alliance Trial Shows Dual Immunotherapy Improves Progression-Free Survival in Advanced Squamous Cell Skin Cancer

Avelumab Plus Cetuximab Combination Meets Primary Endpoint in Phase II Trial A091802, Presented at ASCO 2025 and Published in Journal of Clinical Oncology

May 31, 2025

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival

• Read more

Alliance Research To Be Featured At ASCO 2025

April 24, 2025

Alliance investigators will present more than 20 abstracts at the upcoming 61st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30–June 3, 2025, in Chicago and online. 

This year’s ASCO theme, “Driving Knowledge to Action: Building a Better Future,” emphasizes the vital connection between research and real-world improvements in cancer care. The meeting wil

• Read more